论文部分内容阅读
目的:探讨辛伐他汀对不稳定型心绞痛(UAP)发病早期(24~96h)开始应用的疗效及安全性。方法:临床确诊为UAP患者160例,且血脂水平高于美国国家胆固醇教育计划冠心病预防标准,随机分为对照组(常规治疗,80例)和辛伐他汀组(常规治疗外加服辛伐他汀,80例),于治疗前、治疗后3、6个月时分别测肝功、肾功、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、心血管缺血相关事件。结果:辛伐他汀6个月后能有效地降低UAP患者血清TC、LDL-C,升高HDL-C,与对照组比较有显著性差异(P<0.05),两组患者每周心绞痛发作次数均减少,但辛伐他汀组更明显(P<0.05);其缺血相关事件亦有显著性差异(P<0.05)。结论:UAP发病早期应用辛伐他汀能安全、有效地降低血脂,显著减少心血管缺血相关事件发生率。
Objective: To investigate the efficacy and safety of simvastatin in the early stage of unstable angina pectoris (UAP) onset (24 ~ 96h). Methods: One hundred and six patients with UAP were diagnosed clinically. The levels of serum lipids were higher than those of the National Cholesterol Education Program in the prevention of coronary heart disease. They were randomly divided into control group (n = 80) and simvastatin group , 80 cases). Liver function, renal function, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL- C), cardiovascular related events. Results: Six months after simvastatin, the levels of TC, LDL-C and HDL-C in UAP patients were significantly decreased (P <0.05). The number of patients with angina pectoris (P <0.05). There was also a significant difference in ischemic related events (P <0.05). Conclusion: The application of simvastatin in the early stage of UAP can reduce the blood lipids safely and effectively and reduce the incidence of cardiovascular-related events significantly.